NxStage Kidney Care To Host Grand Opening Event at Greenbelt Dialysis Center - PR Newswire (press release)
NxStage Kidney Care Center in Greenbelt, Maryland
LAWRENCE, Mass., June 16, 2015 /PRNewswire/ -- NxStage Kidney Care, Inc. will host a Grand Opening event at its Greenbelt, Maryland center for dialysis patients and their families, nephrologists, and nephrology nurses on Wednesday, July 15 from 4-6pm. Visitors will have the opportunity to meet the center's highly-trained care team, hear a patient's perspective, and learn about the flexible dialysis therapy options available at the center.
"We are excited to invite local patients and their loved ones to join us in celebrating the Grand Opening of our new center," said Dr. Ashte Collins, Medical Director at NxStage Kidney Care Greenbelt. Dr. Collins is an Assistant Professor of Medicine at The George Washington University (GWU) School of Medicine & Health Sciences. "Our top priority is to provide members of the local kidney community the chance to choose dialysis therapies that meet their personal healthcare needs."
NxStage Kidney Care Greenbelt offers multiple therapy options using the NxStage® System One™, including flexible in-center hemodialysis, home hemodialysis (HHD), home nocturnal hemodialysis, and short-term respite care. The center also offers peritoneal dialysis (PD), along with personalized training for all home therapies offered. The center's renal social worker provides patients with transplant assistance and lifestyle guidance, while the registered dietitian works with them to craft nutritional plans tailored to their needs.
The event will take place at NxStage Kidney Care Greenbelt, located at 10003 Derekwood Lane, Suite 100, Lanham, MD. For more information about NxStage Kidney Care's home and flexible in-center dialysis options please visit www.nxstagekidneycare.com or call (240) 544-0811.
About NxStage Kidney Care NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), is innovating a dialysis care model that is intended to support and encourage patient centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit www.nxstagekidneycare.com or call (866) 694-2707.
About NxStage Medical NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: (978) 332-5923
More than 72 per cent of dialysis patients do not undergo prescribed treatment ... - Financial Express
South India ahead in awareness and adoption of dialysis treatment; cross infection still rampant in the country
While three sessions per week is the globally accepted minimum treatment modality for kidney failure also known as end stage renal disease (ESRD), the majority, 72 per cent of patients in India opt for lesser frequency adversely affecting their longevity and quality of the life states NephroPlus Study. Of the 72 per cent, 65 per cent choose twice a week modality instead of thrice as prescribed and seven per cent opted for once a week modality. As per the findings, the patient behaviour to under-treat themselves is an outcome of their lack of affordability and also understanding of the implications of under-treatment. Clinically, worldwide, it is proven that under treatment puts the patients at risk with most common outcome being cardiac arrest.
The research analyses evolution of dialysis practices and current trends in India. The findings are a result of detailed study conducted amongst over 1,300 patients between January 2013 and July 2014 across 10 states (Andhra Pradesh, Karnataka, Maharashtra, Kerala, Tamil Nadu, Delhi, Telangana, Jharkhand, Uttarakhand and Uttar Pradesh). Out of the centres covered 84 per cent were hospital-based centres and 16 per cent were free-standing centres. Of these, 55 per cent, 28 per cent and 17 per cent, respectively were in tier 1, 2 and 3 cities.
Elaborating about the research, Kamal Shah, Co-founder & Director of Patient Services, NephroPlus said, “With more than two lakh people developing Kidney failure every year, kidney disease is one of the most chronic epidemics to affect the country, but it is widely neglected. While there has been some improvement with few of the state government’s coming forward and subsidising the dialysis treatment, the situation calls for greater participation from state and central governments and also large employers.”
The research also threw light on the quality of treatment. As per the report, around 16 per cent of the dialysis patients across the country were affected by Hepatitis C calling for better quality treatment facilities across the country. Hepatitis C is one of the most dangerous cross infections that dialysis patients get infected.
Study Identifies Human Factors in Surgical Errors Renal and Urology News The most common problems were confirmation bias and failure to understand. The most common precondition problems were hyperfocus on a single issue and inadequate communication. (HealthDay News) -- Surgical never events and contributing human ...
Zacks Rating on Rockwell Medical, Inc. - News Watch International
As much as 4 analysts have advised buy on Rockwell Medical, Inc. (NASDAQ:RMTI) with an average broker rating of 2. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral on the company. Rockwell Medical, Inc. (NASDAQ:RMTI) shares are expected to touch $16.25 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 9.18. The target price could hit $26 on the higher end and $4 on the lower end.
The company has received recommendation from many analysts. 3 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 5.03% or 0.67 points on Monday and made its way into the gainers of the day. After trading began at $13.6 the stock was seen hitting $14.03 as a peak level and $13.33 as the lowest level. The stock ended up at $13.99. The daily volume was measured at 1,102,168 shares. The 52-week high of the share price is $13.35 and the 52-week low is $8.095. The company has a market cap of $702 million.
Several Brokerage firms have commented on company shares. Oppenheimer initiates coverage on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Outperform on the counter. In a recent information released to the investors, Oppenheimer the price target of $24 per share. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
NO COMMENTS
LEAVE A REPLY Cancel reply
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
NxStage Kidney Care Center in Greenbelt, Maryland
